IRCT20141007019432N8 IRCT 2022-03-12 Tehran University of Medical Sciences Epidermal Growth Factor adjuvant therapy for psoriasis EGF; EGFR Evaluation of topical adjuvant treatment of psoriasis with recombinant Epidermal Growth Factor to control the e-regulation of the Epidermal Growth Factor Receptor (EGFR): clinical trial phase 2 2022-04-21 anticipated 21 Complete https://irct.ir/trial/60840 interventional Randomization: Randomized, Blinding: Not blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: Simple randomization, this method is equivalent to tossing a coin for each subject that enters a trial, such as Heads = Active, Tails = Placebo. Implementation and treatment of assignments are completely unpredictable. 2 Psoriasis. Intervention 1: Intervention group: The intervention group will receive a topical cream containing 5% recombinant epidermal growth factor, twice a day for a month. Intervention 2: Control group: the group will be received topical cream which is standard care containing: clobetasol 30gr, urea 15gr, distilled water 15 cc, salycilic acid 1.5 % and eucerin up to100gr, without epidermal growth factor, twice a day for a month. Yes - There is a plan to make this available What will be shared: all data collected for the primary outcome When: data relative to the time after finishing the data collection and 3 months after publication To whom: available for people working in an academic institution Conditions: There is no specific criteria Where to obtain: People can send an email to get more information How to obtain: After requesting the data, you will get an email with information Comments: